Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Connected insulin pen with CGM in diabetes
NCT05893797Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2023
- Primary completion
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of insulin lispro in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Primary endpoint: Number of Missed Bolus Doses Per Week at 18 weeks. Started Oct 2023; status: completed.
02
Drugs
insulin lispro
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05893797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05893797.